Skip to main content

Envisioning is an emerging technology research institute and advisory.

LinkedInInstagramGitHub

2011 — 2026

research
  • Reports
  • Newsletter
  • Methodology
  • Origins
  • Vocab
services
  • Research Sessions
  • Signals Workspace
  • Bespoke Projects
  • Use Cases
  • Signal Scanfree
  • Readinessfree
impact
  • ANBIMAFuture of Brazilian Capital Markets
  • IEEECharting the Energy Transition
  • Horizon 2045Future of Human and Planetary Security
  • WKOTechnology Scanning for Austria
audiences
  • Innovation
  • Strategy
  • Consultants
  • Foresight
  • Associations
  • Governments
resources
  • Pricing
  • Partners
  • How We Work
  • Data Visualization
  • Multi-Model Method
  • FAQ
  • Security & Privacy
about
  • Manifesto
  • Community
  • Events
  • Support
  • Contact
  • Login
ResearchServicesPricingPartnersAbout
ResearchServicesPricingPartnersAbout
  1. Home
  2. Research
  3. Helix
  4. Optogenetic Actuator Kits

Optogenetic Actuator Kits

Light-delivery implants and wearables triggering engineered cells on demand.
Back to HelixView interactive version

Optogenetic actuator kits package miniaturized light sources, fiber optic arrays, and wireless control units for clinical optogenetics applications, enabling precise, on-demand stimulation of cells that have been genetically engineered to respond to light. These systems allow researchers and clinicians to control specific cell types (like neurons or insulin-producing beta cells) with light, enabling applications in neuromodulation, metabolic control, and closed-loop therapeutics where cellular activity can be precisely controlled in response to physiological signals.

This innovation addresses the need for precise, reversible control of cellular activity for therapeutic purposes, where traditional approaches like drugs or electrical stimulation lack specificity or reversibility. By using light to control genetically engineered cells, optogenetics provides unprecedented precision and control. The technology is being developed for applications including treating neurological disorders, controlling metabolism, and creating responsive therapeutic systems. Research institutions and companies are developing these technologies for clinical use.

The technology is particularly significant for treating conditions where precise control of cellular activity is beneficial, potentially providing more effective and safer treatments than traditional approaches. As the technology matures and becomes more accessible, it could enable new treatments for a wide range of conditions. However, ensuring safe gene delivery, managing light delivery systems, and navigating regulatory approval remain challenges. The technology represents a powerful tool for precise biological control, but requires continued development to achieve safe, effective clinical applications. Success could enable new classes of precise, controllable therapies, but the path to clinical use requires careful development of both the genetic engineering and the light delivery systems.

TRL
6/9Demonstrated
Impact
4/5
Investment
4/5
Category
Hardware

Related Organizations

NeuroLux logo
NeuroLux

United States · Startup

98%

A company providing battery-free, wireless optogenetics systems for neuroscience research.

Developer
Doric Lenses

Canada · Company

95%

A global leader in photonics solutions for life sciences, specifically neurophotonics.

Developer
GenSight Biologics

France · Company

95%

A clinical-stage biopharma company focusing on developing therapies for mitochondrial and neurodegenerative diseases of the eye.

Deployer
Mightex

Canada · Company

92%

A company developing innovative all-optical cellular-resolution imaging and stimulation tools for life scientists.

Developer
Plexon

United States · Company

92%

A pioneer and leading innovator of custom, high-performance data acquisition, behavior and analysis solutions for scientific research.

Developer
Blackrock Neurotech logo
Blackrock Neurotech

United States · Company

90%

Manufacturer of the Utah Array, the gold-standard electrode system used in the majority of human BCI research.

Developer
Nanoscope Therapeutics

United States · Startup

90%

A clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases.

Deployer
Bionic Sight

United States · Startup

88%

A company developing a neuro-prosthetic device to treat blindness using optogenetics.

Deployer
Thorlabs

United States · Company

88%

A major manufacturer of photonics equipment, including specific lines for quantum optics research.

Developer
Bruker logo
Bruker

United States · Company

85%

A manufacturer of scientific instruments and superconducting wires (via Bruker EST).

Acquirer

Supporting Evidence

Evidence data is not available for this technology yet.

Connections

Hardware
Hardware
Implantable Bioelectronic Interfaces

Closed-loop neuromodulation implants monitoring inflammatory or metabolic markers.

TRL
4/9
Impact
4/5
Investment
4/5
Hardware
Hardware
Next-Gen In Vivo Gene Delivery Vectors

Organ-targeted viral capsids and lipid nanoparticles enabling safer repeat dosing.

TRL
6/9
Impact
5/5
Investment
5/5

Book a research session

Bring this signal into a focused decision sprint with analyst-led framing and synthesis.
Research Sessions